TCF7L2Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program | Zendy

José C. Florez | Zendy; Kathleen A. Jablonski | Zendy; Nick Bayley | Zendy; Toni I. Pollin | Zendy; Paul I. W. de Bakker | Zendy; Alan R. Shuldiner | Zendy; William C. Knowler | Zendy; David M. Nathan | Zendy; David Altshuler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TCF7L2Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program

Author(s) -

José C. Florez,

Kathleen A. Jablonski,

Nick Bayley,

Toni I. Pollin,

Paul I. W. de Bakker,

Alan R. Shuldiner,

William C. Knowler,

David M. Nathan,

David Altshuler

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa062418

Subject(s) - tcf7l2 , medicine , metformin , diabetes mellitus , type 2 diabetes , impaired glucose tolerance , placebo , endocrinology , oncology , single nucleotide polymorphism , gene , alternative medicine , genetics , genotype , pathology , biology

Common polymorphisms of the transcription factor 7-like 2 gene (TCF7L2) have recently been associated with type 2 diabetes. We examined whether the two most strongly associated variants (rs12255372 and rs7903146) predict the progression to diabetes in persons with impaired glucose tolerance who were enrolled in the Diabetes Prevention Program, in which lifestyle intervention or treatment with metformin was compared with placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research